| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/27/2006 | US20060166870 Treatment of glioblastoma with thymosin-alpha 1 |
| 07/27/2006 | US20060166281 Tissue targeted therapy; identifying antitumor agents specific to transphosphorylase domain of c-kit; interleulin-3 cell targeting |
| 07/27/2006 | US20060166275 Amyloid beta protein (globular assembly and uses thereof) |
| 07/27/2006 | US20060166255 Methods of using 48149, a human Aminopeptidase family member |
| 07/27/2006 | US20060166213 Novel compositions and methods in cancer |
| 07/27/2006 | US20060166194 Diagnosis and treatment of cancer |
| 07/27/2006 | US20060165823 Topical delivery agents and methods for making and using therm |
| 07/27/2006 | US20060165819 Topical composition for the treatment of psoriasis and related skin disorders |
| 07/27/2006 | US20060165793 Pharmaceutical preparation to be dispersed before administration |
| 07/27/2006 | US20060165786 Methods for treating circadian rhythm phase disturbances |
| 07/27/2006 | US20060165771 Compositions for delivery of drug combinations |
| 07/27/2006 | US20060165758 Blunting the postprandial glycemic response by instant feed containing proteins, fats, carbohydrates, neutral soluble dietary fiber (guar gum, pectin, locust bean gum, methylcellulose), and hydrolyzed starch; diabetes |
| 07/27/2006 | US20060165708 Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
| 07/27/2006 | US20060165697 comprising a homeopathically potentised form of polyclonal, antibodies to endothelial nitric oxide synthase (NO synthase) |
| 07/27/2006 | US20060165689 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 07/27/2006 | US20060165684 T-cell immune response cDNA 7 (TIRC7) antagonist; rheumatoid arthritis; comprising all three complementarity determining regions (CDRs) of the VH and all three complementarity determining regions (CDRs) of the VL variable regions; inhibiting proliferation of peripheral blood mononuclear cells |
| 07/27/2006 | US20060165683 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 07/27/2006 | US20060165678 Measuring changes in level of antigen recognizable by a monoclonal antibody or antigen binding fragment; monoclonal antibody is produced by hybridoma cell line; decreased level indicates a reduced tumor; diagnosis, cell purification |
| 07/27/2006 | US20060165671 Novel nutraceutical compositions comprising epigallocatechin gallate |
| 07/27/2006 | US20060165606 Perforated microstructure; efficiently depositing compound at site of action; minimizing toxic side effects, lowering dosing requirements |
| 07/27/2006 | CA2595486A1 Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| 07/27/2006 | CA2595004A1 Remedy for nerve cell regeneration |
| 07/27/2006 | CA2594963A1 Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| 07/27/2006 | CA2594482A1 Antitumor agent |
| 07/27/2006 | CA2592172A1 Modulators of itch ubiquitinase activity |
| 07/26/2006 | EP1683811A2 Compositions and methods for the treatment of tumors |
| 07/26/2006 | EP1683807A1 Combination products for use in antitumoral treatment, comprising an antibody capable of inhibiting the activity of CSF-1 |
| 07/26/2006 | EP1683527A1 Method of inhibiting secretase activity |
| 07/26/2006 | EP1682499A1 4-biarylyl-1-phenylazetidin-2-ones |
| 07/26/2006 | EP1682183A2 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
| 07/26/2006 | EP1682182A1 Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance |
| 07/26/2006 | EP1682181A2 Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
| 07/26/2006 | EP1682176A1 Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| 07/26/2006 | EP1682159A1 Immunomodulating compositions and uses therefor |
| 07/26/2006 | EP1682157A1 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
| 07/26/2006 | EP1682148A1 Use of bh4 for the treatment of respiratory diseases |
| 07/26/2006 | EP1682137A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain |
| 07/26/2006 | EP1682124A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof |
| 07/26/2006 | EP1682123A1 Cancer treatment method |
| 07/26/2006 | EP1682122A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic |
| 07/26/2006 | EP1682104A2 Migraine treatments including isovaleramide compounds and serotonin agonists |
| 07/26/2006 | EP1682098A1 Colonic purgative composition with soluble binding agent |
| 07/26/2006 | EP1682088A1 Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin |
| 07/26/2006 | EP1481065B1 Method for detection of leptin receptor ligands |
| 07/26/2006 | EP1463830A4 Method for classification of anti-psychotic drugs |
| 07/26/2006 | EP1392329B1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 07/26/2006 | EP1383539B1 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 07/26/2006 | EP1359905B1 Use of mglur5 antagonists for the treatment of pruritic conditions |
| 07/26/2006 | EP1353919B1 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 07/26/2006 | EP1353687B1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 07/26/2006 | EP1349457B1 Liquid antimicrobial compositions |
| 07/26/2006 | EP1311297B1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 07/26/2006 | EP1303294B1 Method for treating unstable angina pectoris |
| 07/26/2006 | EP1240313B1 Homologue enzymes of human heparanase and splice variants thereof |
| 07/26/2006 | EP1216025B1 Dispersion formulations containing lipase inhibitors |
| 07/26/2006 | EP1192950B1 Therapeutic drugs for dermatitis exhibiting a biphasic skin reaction containing chymase inhibitors as the active ingredient |
| 07/26/2006 | EP1162937B1 Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration |
| 07/26/2006 | EP1082338B1 17 beta-nitro-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 07/26/2006 | EP1072273B1 Vascularization inhibitors |
| 07/26/2006 | EP1047454B1 Methods of screening compounds useful for prevention of infection or pathogenicity |
| 07/26/2006 | EP0929303B1 Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agent |
| 07/26/2006 | CN1809750A Acetyl-coenzyme A carboxylase 2 as a target in the regulation of fat and insulin action |
| 07/26/2006 | CN1809384A Chemical combination and method for increasing delivery of coenzyme Q 10 |
| 07/26/2006 | CN1809378A Methods for inhibiting viral replication in vivo |
| 07/26/2006 | CN1809367A A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
| 07/26/2006 | CN1809359A Combinations comprising paroxetine and 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or a |
| 07/26/2006 | CN1809355A Combinations comprising paroxetine and 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or a |
| 07/26/2006 | CN1809354A Akt活性抑制剂 Akt activity inhibitor |
| 07/26/2006 | CN1809353A Medicine for prevention of and treatment for arteriosclerosis and hypertension. |
| 07/26/2006 | CN1809340A Pharmaceutical products |
| 07/26/2006 | CN1808106A Method for screening acetylcholine esterase inhibitor by nuclear magnetic resonance |
| 07/26/2006 | CN1807426A Heteroaryl urea neuropeptide y y5 receptor antagonists |
| 07/26/2006 | CN1806849A Method of treating tumors |
| 07/26/2006 | CN1806794A GM-CSF targeted medicine liposome for resisting acute myelogenous leukemia and preparation method thereof |
| 07/26/2006 | CN1266138C Gyrase imhibitors and uses thereof |
| 07/26/2006 | CN1266126C Phenethanolamine derivatives for treatment of respiratory diseases |
| 07/26/2006 | CN1265788C Medicinal compositions |
| 07/26/2006 | CN1265787C Liver-targeting mitomycin magnetic nano-particle and its preparation and application in medicine preparation |
| 07/25/2006 | US7081562 obtained by backcrossing a mouse whose function of immunoglobulin Fc gamma receptor IIB gene is deficient on its chromosome and a wild-type collagen-induced arthritis-susceptible DBA/1J mouse six times or more |
| 07/25/2006 | US7081513 Peptides having Chemotaxis Inhibitory Protein from Staphylococcus aureus (CHIPS) activity for diagnosis, prophylaxis and treatment of inflammation and HIV |
| 07/25/2006 | US7081482 Therapy of disorders of the outer retina by administering a pharmaceutically effective amount of a beta -adrenoceptor antagonist |
| 07/25/2006 | US7081479 Treatment of acne using alkonolamine compositions |
| 07/25/2006 | US7081471 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 07/25/2006 | US7081467 C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals |
| 07/25/2006 | US7081460 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 07/25/2006 | US7081454 Anticancer agents |
| 07/25/2006 | US7081351 Immobilized and labeled; detection cell differentiation, cell proliferation; prevent binding to fibroblast growth factor |
| 07/25/2006 | US7081258 Composition for promoting hair growth |
| 07/25/2006 | US7081240 Protein mixtures for wound healing |
| 07/25/2006 | US7081239 Administering formulation comprising peptide YY or antagonists of receptors for peptide YY for manipulating the rate of upper gastrointestinal transit of a substance in a mammal having an intrinsic cholinergic afferent neural pathway |
| 07/20/2006 | WO2006076240A2 Compositions, products and methods for controlling weight in a mammal |
| 07/20/2006 | WO2006076019A1 Treatment of behavioral disorders |
| 07/20/2006 | WO2006075776A1 Therapeutic agent for chronic obstructive pulmonary disease (copd), cystic fibrosis or pulmonary hypertension |
| 07/20/2006 | WO2006075165A1 Combination of oncolytic viruses with angiogenesis inhibitors |
| 07/20/2006 | WO2006065513A3 Oral treatment compositions containing an anti-adhesion agent, antibacterial agent and incompatible compound |
| 07/20/2006 | WO2005120553A3 Insulin-independent, bone morphogenetic protein (bmp)-mediated uptake of blood glucose by peripheral cells and tissues |
| 07/20/2006 | WO2005102392A3 Combinations for treating hiv infection |
| 07/20/2006 | WO2005097190A3 Systems and methods for providing a stem cell bank |
| 07/20/2006 | WO2005058363A3 Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor |
| 07/20/2006 | WO2005051297A3 Combination drug therapy to treat obesity |